Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health.
Anatara is a specialist life sciences company with expertise in developing products for human and animal health. We are currently focused on building a pipeline of evidence-based, gastrointestinal health products.
Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
We’re delighted to share that Stage 1 of the GaRP Irritable Bowel Syndrome (IBS) trial has reached its interim. These results were announced late September 2023, and we’re encouraged by the absence of significant safety concerns. Our commitment to improving lives through research is stronger than ever.
At Antara, our mission is clear: to pioneer breakthrough treatments for those suffering from gastrointestinal health issues.
Our team is driven by a shared passion for improving lives and transforming the landscape of gastrointestinal healthcare. Together, we bring diverse expertise, unwavering dedication, and a commitment to innovation.
Our team of researchers and scientists are at the forefront of gastrointestinal health research. With diverse backgrounds in biology, chemistry, and pharmacology, they worked tirelessly to develop the next generation of treatments.
We’ve now moved onto clinical research teams who match our level of passion for this exciting treatment.
Our Investor Center section is designed to provide you with the resources and knowledge you need for a successful partnership with us.